Amsterdam University Medical Center

The Amsterdam University Medical Center and its associated research facility, the Cancer Center Amsterdam (CCA), are leading European institutions dedicated to the fight against brain cancer offering high-quality patient care, innovative scientific research, and teach the cancer health professionals of the future. Their core belief is that clinical practice, research, and education are deeply interconnected – each shaping and enhancing the other to care for thousands of brain cancer patients at our institution every year.

Within Amsterdam UMC, the Department of Radiology and Nuclear Medicine (RNG) strives to advance medical imaging through the development and validation of cutting-edge AI tools and advanced imaging techniques, bridging the gap from bench to bedside. Its state-of-the-art Imaging Center is home to the latest hybrid imaging technologies, not only developing innovative tools, but also supporting drug development and the education of the next generation imaging experts. Their physician scientists collaborate closely with internal and external colleagues from Neuro-Oncology, Neurosurgery and Radiation Oncology worldwide as well as being members of the CCA to guarantee impactful and translational research. The CCA has unique expertise that is not available elsewhere in the region and pushes the boundaries of oncology research.

A collaborative effort between the RNG, CCA, the Departments of Pathology, Neurosurgery and Neuro-Oncology, the IMAGO project is a large-scale, open-source glioma database. Developed by a multidisciplinary team of clinically and scientifically active physicians, IMAGO contains data from over 1,400 patients – making it a unique and invaluable resource for research. IMAGO sets itself apart as it contains pre-operative, post-operative, and longitudinal follow-up clinical information along with extensive MRI data. Designed as a continuously evolving resource, the database will be iteratively expanded with new anonymized, GDPR-compliant patient data, ensuring its long-term relevance and impact on glioma research.

Role of institution in the project

AUMC expertise lies in brain tumor imaging and advanced imaging with MRI including processing and data presentation for further use (BIDS, OSIPI acitivity). They have also a lot of experience with interdisciplinary coordination in Neuro-Oncology and developing multicenter projects.

Vera Keil

Vera Keil, M.D., Ph.D., (*1985) is a German-born Neuroradiologist and work group leader at Amsterdam UMC. As a CCA-associated PI her work focuses on advanced imaging and neuro-oncological imaging in both adults and children (collaborating with Prague-situated project PediTuMRI). Her research lines embrace several perfusion techniques, relaxometry, diffusion, APT-CEST, and artificial intelligence with an emphasis on their clinical application such as finding alternatives for contrast agent injection in patient care (projects REDUCE, DEBBIE-ASL and GLIOCARE). Dr. Keil received more than 1.2 M Euros in research funding from Dutch and International institutions. She is a board member of the ESMRMB, ISMRM Benelux, GliMR ESMRMB working group and the Dutch association of Neuroradiology as well as a distinguished reviewer to numerous journals and junior deputy editor for European Radiology. Dr. Keil was an invited lecturer at numerous occasions (ECR, ESNR annual meeting, TACTIX Twinning grant, among others). She authored to date (Jan 2025) 60 peer-reviewed articles and three book chapters.

Ivar Wamelink

Ivar Wamelink, born 1996, is a technical physician who received his MSc in Technical Medicine at the University of Twente. With a background in neuro-oncology, imaging, and artificial intelligence, he is currently finishing his PhD at the Department of Radiology and Nuclear Medicine at Amsterdam University Medical Center, working on the GLIOCARE and IMAGO projects. The GLIOCARE project focuses on the reduction of gadolinium-based contrast agent usage during diagnosis and follow-up of glioma patients, using advanced MRI such as APT-CEST (amide-proton transfer chemical exchange saturation transfer), ASL (arterial spin labeling), and artificial intelligence. The IMAGO project is a large glioma database that is currently made public. He has actively participated in setting up meetings for the GliMR 2.0 network, now an ESMRMB working group.

Dr. Philipp Seeböck

Frederik Barkhof, M.D., Ph.D., born 1962, is a full Professor in Neuroradiology at the Department of Radiology & Nuclear Medicine at the Amsterdam UMC and at the Institute of Biomedical Engineering and Neurology at University College London (UK) to translate novel imaging techniques. He obtained his PhD in 1992 for which he received the Philips Prize for Radiology (1992) and the Lucien Appel Prize for Neuroradiology (1994). His main research interest has been multiple sclerosis for which he has been awarded several highly-distinguished prizes such as the John Dystel prize (2018). Prof. Barkhof’s research focus expanded to include childhood white matter disease, dementia and neuro-oncology, among others. In neuro-oncology, he leads a research team that focuses on the improvement of glioma diagnosis, follow-up, and surgical treatment through advanced MRI and artificial intelligence. He (co)authored >1100 publications referenced in PubMed, has an h-factor of 164 (Google Scholar) with >110,000 citations and is listed among 3000 most influential scientists world-wide by Thompson-Reuters.

Pieter Wesseling

Pieter Wesseling, M.D., Ph.D, is a (neuro)pathologist and full professor at the Department of Pathology at the Amsterdam UMC, and is additionally affiliated with the Princess Máxima Center for Pediatric Oncology in Utrecht. Wesseling was trained as clinical (neuro)pathologist in the Radboud University Medical Center in Nijmegen (supervised by Prof. Joop L. Slooff), and at Duke University Medical Center in Durham, NC, USA (Prof. Peter C. Burger. He has led multiple (inter)national research projects, (co-)authored more than 300 papers in international, peer-reviewed journals on neuro-oncological topics, is member of the editorial board of several international neuro-oncological and neuropathological journals. He is, at present, chair of the consortium to Improve Molecular and Practical Approaches for CNS tumor Taxonomy (cIMPACT-NOW) Steering Committee. He was centrally involved in shaping the revised 4th edition of the WHO CNS tumor classification (2016) and is an expert editor of the 5th (2021) edition of this classification as well as of the WHO classification of Pediatric Tumors (2022).

Join the EUCAIM Consortium

Open Call for New Beneficiaries

We’re inviting new partners to enhance our pan-European infrastructure for cancer images and artificial intelligence.

Whether you’re a data holder with valuable cancer images or an innovator developing AI tools for precision medicine, this is your chance to contribute to a groundbreaking project.

Apply by 10 June 2024!

Find out more

Open Call Webinar

We recently hosted a webinar with more details for prospective applicants to the open call. A recording is available.

WATCH THE RECORDING

Our open Call for new collaborators
launches in April 2024

Opportunities for data holders & AI developers to contribute await! Let‘s join forces to enhance cancer diagnosis and treatment

Be the first to know and apply!

Sign up for more information

SAVE THE DATE
March 14, 10:00-11:30 aM CET

DISCOVER THE CANCER IMAGE EUROPE PLATFORM

TECHNICAL DEMONSTRATION WEBINAR

Explore the potential for AI-driven cancer care advancements!
Learn how to access and utilize our federated cancer image repository. The webinar is for AI Innovators & Data Providers interested in the platform and will feature an introduction to EUCAIM & Cancer Image Europe and a demonstration of data exploration & access.

Survey Invitation

Join Leading Experts In Shaping AI In Cancer

EUCAIM is looking for your feedback! We have recently published a Stakeholder Survey in order to reach out to potential end-users and stakeholders. We believe that your insights could significantly contribute to understanding the expectations of potential users and identifying the essential aspects that stakeholders find crucial for future engagement and collaboration with the platform.

Therefore, we would like to invite you to participate in the Stakeholder Survey about the Cancer Image Europe platform.

Completing the survey will take approximately 10 minutes. Your participation is crucial to the success of this project, and we deeply appreciate your expertise in shaping the future of cancer imaging and treatment.

Participate